Clinicopathological analysis of salivary gland carcinomas and literature review

  • Authors:
    • Hideo Shigeishi
    • Kouji Ohta
    • Gaku Okui
    • Sayaka Seino
    • Miho Hashikata
    • Kazuhiro Yamamoto
    • Yoko Ishida
    • Kazuki Sasaki
    • Takako Naruse
    • Mohammad Zeshaan Rahman
    • Ryo Uetsuki
    • Akiko Nimiya
    • Shigehiro Ono
    • Hiroshi Shimasue
    • Koichiro Higashikawa
    • Masaru Sugiyama
    • Masaaki Takechi
  • View Affiliations

  • Published online on: October 9, 2014     https://doi.org/10.3892/mco.2014.441
  • Pages: 202-206
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Malignant salivary gland tumors are rare and exhibit a broad spectrum of phenotypic heterogeneity. The objective of this study was to investigate prognostic factors in patients with salivary gland carcinomas and review the results in light of other reports. We retrospectively reviewed 40 patients with primary salivary gland carcinomas who were diagnosed and treated at our institution between 1991 and 2014. Of the 40 tumors, 19 (47.5%) were mucoepidermoid carcinomas, 11 (27.5%) were adenoid cystic carcinomas, 7 (17.5%) were acinic cell carcinomas, 2 (5.0%) were myoepithelial carcinomas and 1 (2.5%) was a squamous cell carcinoma. Clinically positive lymph nodes were present in 4 patients (10.0%). As regards clinical stage, 15 cases (37.5%) were stage I, 13 (32.5%) were stage II, 1 (2.5%) was stage III and 11 (27.5%) were stage IVA. The majority of the patients (97.5%) were treated with surgery, of whom 25 (62.5%) received surgery alone and 14 (35.0%) underwent surgery in combination with chemotherapy or chemotherapy and radiotherapy. The median follow‑up time for all the patients was 48 months. The disease‑specific survival rate at 5 years was 87.1%. We identified a significant correlation between poor survival rate and histological grade (intermediate/high), tumor size (T3/T4), lymph node metastasis (node‑positive) and clinical stage (III/IV) using the Kaplan‑Meier method (P<0.05 for each). In addition, the Cox proportional hazards regression analysis confirmed that lymph node metastasis and tumor size were independent prognostic factors for disease‑specific survival (hazard ratio = 18.7 and 15.1, respectively; P=0.023 and 0.037, respectively). Furthermore, tumor size was found to be a predictive factor regarding recurrence in the multivariate logistic regression analysis (odds ratio = 8.35; P=0.025). Our results suggest that lymph node metastasis and tumor size are significant prognostic factors for patients with salivary gland carcinomas.
View References

Related Articles

Journal Cover

January-February 2015
Volume 3 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shigeishi H, Ohta K, Okui G, Seino S, Hashikata M, Yamamoto K, Ishida Y, Sasaki K, Naruse T, Rahman MZ, Rahman MZ, et al: Clinicopathological analysis of salivary gland carcinomas and literature review. Mol Clin Oncol 3: 202-206, 2015
APA
Shigeishi, H., Ohta, K., Okui, G., Seino, S., Hashikata, M., Yamamoto, K. ... Takechi, M. (2015). Clinicopathological analysis of salivary gland carcinomas and literature review. Molecular and Clinical Oncology, 3, 202-206. https://doi.org/10.3892/mco.2014.441
MLA
Shigeishi, H., Ohta, K., Okui, G., Seino, S., Hashikata, M., Yamamoto, K., Ishida, Y., Sasaki, K., Naruse, T., Rahman, M. Z., Uetsuki, R., Nimiya, A., Ono, S., Shimasue, H., Higashikawa, K., Sugiyama, M., Takechi, M."Clinicopathological analysis of salivary gland carcinomas and literature review". Molecular and Clinical Oncology 3.1 (2015): 202-206.
Chicago
Shigeishi, H., Ohta, K., Okui, G., Seino, S., Hashikata, M., Yamamoto, K., Ishida, Y., Sasaki, K., Naruse, T., Rahman, M. Z., Uetsuki, R., Nimiya, A., Ono, S., Shimasue, H., Higashikawa, K., Sugiyama, M., Takechi, M."Clinicopathological analysis of salivary gland carcinomas and literature review". Molecular and Clinical Oncology 3, no. 1 (2015): 202-206. https://doi.org/10.3892/mco.2014.441